Interferon and Ribavirin both have serious and dangerous side effects, and are currently the only available treatments (or part of those treatments) available to persons with chronic hepatitis C.
Newly developed drugs, used in conjunction with each other, indicate successful cure rates without such serious and dangerous side-effects.
Two recently approved drugs, Simeprevir and Sofosbuvir
produced high sustained response rates for hard-to-treat patients in a COSMOS trial, when used together WITHOUT Interferon and Ribavirin.
Daclatasvir (still in phase III testing) and Sofosbuvir produced even higher sustained response rates in phase II trials when used together WITHOUT Interferon and Ribavirin.
Make these non Interferon OR Ribavirin treatments available and affordable to all.
This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.
